Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy

Table 3 Nanomedical approaches to mRNA delivery

Application	Main components of vector	Size (nm)	Route	mRNA dosage	Status	References
mRNA vaccine	ALC-0315	Not found	I.M.	30 µg (For humans)	Market	[8]
	SM-102	Not found	I.M.	50 µg (For humans)	Market	[26]
	Cholesterol, phosphatidylserine	< 200	S.C.	12 µg	Completed	[20]
Protein replacement	PEG-PAsp(DET)	100	I.C.V.	3 µg	Completed	[85]
	Biodegradable ionizable lipids (ATX)	Undisclosed	I.V.	2 and 4 mg/kg	Completed	[86]
	Phospholipids, cholesterol, PEG	< 100	I.V.	190 and 760 ng	Completed	[87]
mRNA antibody	DSPC, cholesterol and PEG-lipid	Undisclosed	I.V.	0.1, 0.3 and 0.6 mg/kg	Active(Phase I)	[88]
	DOTAP, cholesterol	183–339	I.T.	5 µg	Completed	[89]
	DSPC, cholesterol and PEG-lipid	88.99	I.V.	0.2 and 1 mg/kg	Completed	[90]
	TransIT-mRNA Transfection kit	Undisclosed	I.V.	5 µg	Completed	[91]
Gene delivery and editing	Cationic ionizable lipids, phospholipids, cholesterol	150	I.V.	0.1 mg/kg	Completed	[92]
Gene delivery and editing	306-O12B (A leading tail-branched bioreducible lipidoid)	110	I.V.	3 mg/kg	Completed	[93]

S.C. subcutaneous injection, I.C.V. intracerebroventricular administration, I.V. intravenous injection, I.T. intratracheally administration

ISSN: 1479-5876